HR Execs on the Move

Cellenkos Incorporated

www.cellenkosinc.com

 
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Simrit Parmar
Founder Profile

Similar Companies

Polaris Pharmacy Services

Polaris Pharmacy Services is a leading provider of long term care pharmacy solutions in the United States. They offer enhanced clinical services, a client web portal, a web-based discharge program, HIPAA compliant communication, ePrescribing, and educa...

Data Health USA

Data Health USA is a Ashland, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deutsches Altenheim

Deutsches Altenheim is a West Roxbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comprehensive Mental Health

Comprehensive Mental Health is a Muncie, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Naveos

NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.